Trial Information - Phase II
A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Disease Specifics: NSCLC
Protocol ID: 849-007
Sponsor: Mirati Therapeutics, Inc.
Status: STAR Trial
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724